Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more


(Plasmid #160656)


Item Catalog # Description Quantity Price (USD)
Plasmid 160656 Standard format: Plasmid sent in bacteria as agar stab 1 $85 *

* Login to view industry pricing.


  • Vector backbone
  • Backbone size w/o insert (bp) 3482
  • Total vector size (bp) 4082
  • Vector type
    Bacterial Expression

Growth in Bacteria

  • Bacterial Resistance(s)
    Ampicillin, 100 μg/mL
  • Growth Temperature
  • Growth Strain(s)
  • Growth instructions
    Growth at 37C or addition of nalidixic acid induces NSP8 expression
  • Copy number
    High Copy


  • Gene/Insert name
    SARS-CoV-2 NSP8
  • Alt name
    Severe acute respiratory syndrome coronavirus 2 non-structural protein 8
  • Species
  • Insert Size (bp)
  • Entrez Gene
    ORF1ab (a.k.a. GU280_gp01)

Resource Information

  • A portion of this plasmid was derived from a plasmid made by
    Codon optimized NSP8 gene was ordered from Genscript.
  • Articles Citing this Plasmid

Terms and Licenses

  • Zeocin® is an InvivoGen trademark.
How to cite this plasmid ( Back to top)

These plasmids were created by your colleagues. Please acknowledge the Principal Investigator, cite the article in which the plasmids were described, and include Addgene in the Materials and Methods of your future publications.

  • For your Materials & Methods section:

    pcI-ts,ind+-(NSP8) was a gift from Kenneth Johnson (Addgene plasmid # 160656 ; ; RRID:Addgene_160656)
  • For your References section:

    Remdesivir Is Effective in Combating COVID-19 because It Is a Better Substrate than ATP for the Viral RNA-Dependent RNA Polymerase. Dangerfield TL, Huang NZ, Johnson KA. iScience. 2020 Nov 28:101849. doi: 10.1016/j.isci.2020.101849. 10.1016/j.isci.2020.101849 PubMed 33283177